Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1

European Journal of Pharmacology

Volumn 547, Issue 1-3, 2006, Pages 192-199

  Green, Brian D ^b   Irwin, Nigel ^a   Duffy, Nicola A ^a   Gault, Victor A ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Diabetes; Dipeptidyl peptidase IV; Incretin hormone; Insulin; Metformin

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; METFORMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; IC 50; INSULIN BLOOD LEVEL; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MICE; MICE, OBESE; TIME FACTORS;

EID: 33748531290     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.07.043     Document Type: Article

References (42)

1. Ahren B., and Hughes T.E. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 146 (2005) 2055-2059
2. Ahren B., and Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 36 (2004) 867-876
3. Ahren B., Gomis R., Standl E., Mills D., and Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
4. Bailey C.J. Biguanides and NIDDM. Diabetes Care 15 (1992) 755-772
5. Bailey C.J., and Flatt P.R. Development of antidiabetic drugs. In: Ioannides C., and Flatt P.R. (Eds). Drugs, Diet and Disease: Mechanistic Approaches to Diabetes (1995), Ellis Horwood, London 279-326
6. Bailey C.J., and Turner R.C. Metformin. N. Engl. J. Med. 334 (1996) 574-579
7. Bailey C.J., Flatt P.R., and Atkins T.W. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 6 (1982) 11-21
8. Bailey C.J., Flatt P.R., and Ewan C. Anorectic effect of metformin in lean and genetically obese hyperglycaemic (ob/ob) mice. Arch. Int. Pharmacodyn. Ther. 282 (1986) 233-239
9. Burington R.S. Handbook of Mathematical Tables and Formulas (1973), McGraw-Hill, New York
10. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A., and Zhang B.B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6825-6830
11. Cusi K., and DeFronzo R.A. Metformin: a review of its metabolic effects. Diabetes Rev. 6 (1998) 89-131
12. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80 (1995) 952-957
13. De Meester I., Korom S., Van Damme J., and Scharpe S. CD26, let it cut or cut it down. Immunol. Today 20 (1999) 367-375
14. Edmondson S.D., Mastracchio A., Beconi M., Colwell Jr. L.F., Habulihaz B., He H., Kumar S., Leiting B., Lyons K.A., Mao A., Marsilio F., Patel R.A., Wu J.K., Zhu L., Thornberry N.A., Weber A.E., and Parmee E.R. Potent and selective proline derived dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 5151-5155
15. Flatt P.R., and Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 5 (1981) 573-577
16. Fujiwara K., and Tsuru D. New chromogenic and fluorogenic substrates for pyrrolidonyl peptidase. J. Biochem. 83 (1978) 1145-1149
17. Gorrell M.D., Gysbers V., and McCaughan G.W. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. 54 (2001) 249-264
18. Green B.D., Gault V.A., O'Harte F.P.M., and Flatt P.R. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. 10 (2004) 3651-3662
19. Green B.D., Gault V.A., O'Harte F.P.M., and Flatt P.R. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Brit. J. Diabetes Vasc. Dis. 5 (2005) 134-140
20. Haacke W., Kullertz G., and Barth A. Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers. Arch. Geschwulstforsch. 56 (1986) 145-153
21. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., and Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004) 1326-1335
22. Hinke S.A., Kuhn-Wache K., Hoffmann T., Pederson R.A., McIntosh C.H., and Demuth H.U. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem. Biophys. Res. Commun. 291 (2002) 1302-1308
23. Hui H., Wright C., and Perfetti R. Glucagon-like peptide-1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50 (2001) 785-796
24. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
25. Lee A., and Morley J.E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes. Res. 6 (1998) 47-53
26. Lenhard J.M., Croom D.K., and Minnick D.T. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem. Biophys. Res. Commun. 324 (2004) 92-97
27. Lindsay J.R., Duffy N.A., McKillop A.M., Ardill J., O'Harte F.P.M., Flatt P.R., and Bell P.M. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet. Med. 22 (2005) 654-657
28. Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., Pierazzuoli E., Ciani S., Messeri G., and Rotella C.M. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24 (2001) 489-494
29. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6874-6879
30. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H., O'Harte F.P.M., Yoon T.W., Swanston-Flatt S.K., and Flatt P.R. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45 (1996) 1132-1140
31. Meneilly G.S., Demuth H.U., McIntosh C.H., and Pederson R.A. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet. Med. 17 (2000) 346-350
32. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85 (1999) 9-24
33. Paolisso G., Amato L., Eccellente R., Gambardella A., Tagliamonte M.R., Varricchio G., Carella C., Giugliano D., and D'Onofrio F. Effect of metformin on food intake in obese subjects. Eur. J. Clin. Investig. 28 (1998) 441-446
34. Rouru J., Huupponen R., Pesonen U., and Koulu M. Subchronic treatment with metformin produces anorectic effect and reduces hyperinsulinemia in genetically obese Zucker rats. Life Sci. 50 (1992) 1813-1820
35. Ruter J., Hoffmann T., Demuth H.U., Moschansky P., Klapp B.F., and Hildebrandt M. Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase IV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice. Biol. Chem. 385 (2004) 537-541
36. Stevens J.F. Determination of glucose by an automatic analyser. Clin. Chim. Acta 32 (1971) 199-201
37. Stumvoll M., Nurjhan N., Periello G., Dailey G., and Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333 (1995) 550-554
38. UK Prospective Diabetes Study. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
39. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., and Tanaka I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem. Biophys. Res. Commun. 298 (2002) 779-784
40. Zander M., Taskiran M., Toft-Nielsen M.B., Madsbad S., and Holst J.J. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24 (2001) 720-725
41. Zhou J., Wang X., Pineyro M.A., and Egan J.M. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48 (1999) 2358-2366
42. Zhu L., Tamvakopoulos C., Xie D., Dragovic J., Shen X., Fenyk-Melody J.E., Schmidt K., Bagchi A., Griffin P.R., Thornberry N.A., and Sinha Roy R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J. Biol. Chem. 278 (2003) 22418-22423